Clinical trials: Human Papilloma Virus Infection
Uterine Cervical Cancer
Community Awareness, Resources and Education (CARE II): Project 3
Researchers at The Ohio State University and the University of Michigan are working together to understand cancer of the cervix.
- Trial name
- NCT01299714
- Where
- 4 sites in United States
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Human Papillomavirus Infection, Human Papillomavirus Infections
Papilozumib Vaginal Gel for Exocervical Mucosal Restoration in Women With Human Papillomavirus (HPV)
This randomized, open-label, multicenter clinical study is designed to evaluate Papilozumib® vaginal gel in women aged 30 to 50 years who test positive for human papillomavirus (HPV) and present with either normal cervical…
- Trial name
- NCT07762209
- Testing
- Papilozumib vaginal gel, Papilozumib oral supplement
- Where
- 6 sites in Spain
- Volunteers
- 81 people
- Sponsor
- Hifas da Terra S.L.
HPV Infections
V501 Efficacy Study in Women Aged 18 to 26 (V501-027)
A study to evaluate the efficacy, immunogenicity, safety and tolerability of V501 in adult women
- Trial name
- NCT00378560
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 1,021 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer, Papilloma Viral Infection
Reducing Urban Cervical Cancer Disparities
This study uses a hybrid Type 1 effectiveness-implementation trial to operationalize and assess the efficacy of the Health Enhancement Resource System (HERS) intervention.
- Trial name
- NCT06416150
- Testing
- Stage 1 SOC, Stage 1 HERS, Stage 2 HERS
- Where
- 3 sites in United States
- Volunteers
- 546 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Papilloma Viral Infection, Vaccine Hesitancy
Communication Strategies to Increase HPV Vaccinations
This research aims to identify communication strategies to improve the uptake of vaccines using an experimental design, focusing on the Human Papillomavirus (HPV) vaccine, which is highly effective in preventing HPV-related…
- Conditions
- Papilloma Viral Infection, Vaccine Hesitancy, Communication
- Trial name
- NCT06784960
- Testing
- HPV Message 1, HPV Message 2, HPV Message 3
- Where
- United States
- Volunteers
- 9,002 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Human Papilloma Virus
Zinc Sulfate for Human Papillomavirus (HPV)
The Human Papillomavirus (HPV) is well established as the primary causative agent in both warts and cervical cancer. Although cervical high risk HPV (hrHPV) infections have a high rate of spontaneous resolution this takes time…
- Trial name
- NCT03404310
- Testing
- Zinc Sulfate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Corewell Health West
Papillomavirus Infections
Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)
The primary objective of this study is the estimation of the human papillomavirus (HPV) 6, 11, 16, 18, 31, 33, 45, 52 and 58 seroconversion at 1 month post last dose (Month 7) following 3 doses and 2 doses of the 9-valent human…
- Trial name
- NCT04772534
- Testing
- 9vHPV vaccine
- Where
- 12 sites in Japan
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Immunodeficiency Virus, Human Papilloma Virus
The Prevalence of Oral HPV Infection and Oral Lesions in People Living With HIV
The study will evaluate 300 people living with HIV that attend the Vivent Clinic for HIV care. We will characterize our population and include age, race/ethnicity, sex at birth, tobacco use, alcohol use, other comorbidities, HPV…
- Trial name
- SWISH (NCT06205511)
- Testing
- Oral HPV Sample
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- Vivent Health
Human Papillomavirus (HPV) Vaccine
Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Healthy Vietnamese Women According to a 0, 1, 6 Month Schedule
The purpose of this study is to assess the occurrence of serious adverse events (SAEs) as well as evaluate the occurrence of solicited local and solicited general symptoms and the occurrence of medically significant conditions…
- Trial name
- HPV-022 PRI (NCT00572000)
- Testing
- HPV-16/18 L1 VLP AS04 vaccine
- Where
- Vietnam
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- National Institute for Control of Vaccine and Biologicals
Cervical Intraepithelial Neoplasia, Papillomavirus Infection
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine
This protocol posting deals with objectives \& outcome measures of the extension phase up to Month 48. The objective of the extension study is to evaluate the long-term immunogenicity of the HPV 16/18 L1 VLP AS04 vaccine (for all…
- Trial name
- NCT00316706
- Testing
- GSK Biologicals' HPV-16/18 Vaccine (Cervarix™), Havrix™
- Where
- 28 sites in Colombia, Germany and 3 more
- Volunteers
- 1,245 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Transgenderism, Cervical Cancer
Implementing HPV DNA Self-Collection to Increase Rates of Cervical Cancer Screening in Transgender Men
Transgender men are individuals born genetically female that have a gender identity that is incongruent with their biological sex.
- Conditions
- Transgenderism, Cervical Cancer, Human Papilloma Virus
- Trial name
- NCT04154358
- Testing
- HPV testing
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Augusta University
Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia
Long-Term Immune Persistence After Bivalent HPV Vaccination in Females From Study 311-HPV-1005
This is a single-center, open-label, prospective observational extension of Study 311-HPV-1005 (NCT04965350). The study follows females who received at least one dose of a bivalent human papillomavirus vaccine containing HPV-16…
- Trial name
- NCT07833852
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Pichia pastoris)
- Where
- China
- Volunteers
- 486 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
HPV Infection, HIV Infection
Human Papillomavirus Infection and Knowledge and Attitudes About HPV Vaccines Among Men Who Have Sex With Men (MSM)
This is a observational study aims to assess anal and genital human papillomavirus (HPV) infection status among men who have sex with men (MSM) in China, and their knowledge and attitude about HPV vaccine.
- Conditions
- HPV Infection, HIV Infection, Syphilis
- Trial name
- NCT01300689
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
Cervical Cancer, Vulvar Cancer
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 4-valent and 9-valent HPV recombinant vaccine in Chinese healthy females 20 to 45 years of age.
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT04425291
- Testing
- 4-valent HPV Vaccine, 9-valent HPV Vaccine, GARDASIL®
- Where
- China
- Volunteers
- 1,680 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Genital Warts
Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts
The purpose of this study is to compare the recurrence rate following total clearance of external genital warts (EGWs) when clearance has been obtained by imiquimod (3 applications per week for 4 weeks) followed by ablative…
- Trial name
- NCT00189293
- Testing
- Imiquimod, vehicle cream
- Where
- 12 sites in Italy
- Volunteers
- 128 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
HPV Infections
Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)
A study to test the safety and effectiveness of Quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine against combined incidence of HPV 6/11/16/18-related persistent infection and vaccine type-specific genital disease among…
- Trial name
- NCT00834106
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 3,006 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV Infection, Cervical Cancer
HPV-Based Screen-and-Treat Demonstration Project in Lilongwe
The purpose of this study is to assess completion and performance of the following novel invasive cervical cancer (ICC) screen-and-treat algorithm among 625 HIV-positive women in Lilongwe, Malawi: 1) rapid testing of…
- Conditions
- HPV Infection, Cervical Cancer, HIV Infections
- Trial name
- NCT04092257
- Testing
- VIA and thermocoagulation
- Where
- Malawi
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Immunization, Efficacy
GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose
The investigators are evaluating whether 15-26 year old males and females need a 3rd dose of the human papillomavirus (HPV) vaccine, or whether 2 doses provide similar protection as 3 doses from the 9 types of HPV that it…
- Conditions
- Immunization, Efficacy, Human Papilloma Virus
- Trial name
- NCT03943875
- Testing
- 9-valent HPV vaccine, 2 dose efficacy, 9-valent HPV vaccine, 3 doses standard timing
- Where
- United States
- Volunteers
- 767 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Cervical Cancer, HPV Infection
1:1 Comparison of the Pocket Colposcope in Kenya
The Pocket colposcope has 510k FDA clearance and has been successfully used in almost 1500 unique patients globally in Duke and non-Duke protocols to date.
- Conditions
- Cervical Cancer, HPV Infection, HIV Infections
- Trial name
- NCT04998318
- Testing
- Pocket Colposcope, Standard of Care Colposcopy
- Where
- Kenya
- Volunteers
- 434 people
- Sponsor
- Duke University
Papillomavirus Infections, Genital Diseases, Female
Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)
This study was conducted in 2 parts. Part A was a randomized, double-blind, placebo-controlled, multicenter, sequential dose-escalating evaluation.
- Trial name
- NCT00365716
- Testing
- Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20, Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40, Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80
- Volunteers
- 1,158 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.